2024 Foresight ASCO | A list of major research in the field of urologic oncology in China

The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, the "Oscar" of the oncology community, will be held in Chicago, USA from May 31 to June 4 local time. This article will take you into the urology session of the ASCO conference to "foresee" those upcoming Chinese studies and LBA blockbuster studies!

Voice of China

Kidney and bladder cancer

01

Abstract No.: 4511

标题：Camrelizumab plus apatinib for previously treated advanced adrenocortical carcinoma: A single-arm, open-label, phase 2 trial.

Camrelizumab in Combination With Apatinib in Previously Treated Advanced Adrenal Cortical Carcinoma: A Single-arm, Open-Label, Phase II Trial.

Speaker: Wei Zhigong

Affiliation: West China Hospital, Sichuan University

02

Abstract: 4522

标题：Multi-omics analyses and molecular subtypes to provide potential therapeutic implications in fumarate hydratase-deficient renal cell carcinoma.

Multiomics analysis and molecular subtypes provide potential therapeutic implications for fumarate hydratase-deficient renal cell carcinoma.

Speaker: Xingming Zhang

Affiliation: West China Hospital, Sichuan University

03

Abstract: 4523

标题：Sintilimab plus axitinib for advanced fumarate hydratase-deficient renal cell carcinoma: A multi-center, open-label, single-arm, phase II study (SAFH).

Sintilimab in Combination With Axitinib in Advanced Fumarate Hydratase-Deficient Renal Cell Carcinoma: A Multicenter, Open-label, Single-arm, Phase II Study (SAFH).

Speaker: Zeng Hao

Affiliation: West China Hospital, Sichuan University

04

Abstract:4537

标题：Belzutifan plus lenvatinib (len) for Chinese patients (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC): Preliminary results of cohort 1 of the phase 1 LITESPARK-010 study.

Belzutifan in combination with lenvatinib in patients with previously treated advanced clear cell renal cell carcinoma in China: preliminary results from the Phase I cohort of the LITESPARK-010 study.

Speaker: Sheng Xinan

Affiliation: Peking University Cancer Hospital

05

Summary No.: 4539

标题：Camrelizumab plus apatinib for advanced renal cell carcinoma patients after first-line tyrosine kinase inhibitor treatment failure: A multicenter phase II trial.

Camrelizumab plus apatinib in patients with advanced renal cell carcinoma after failure of first-line tyrosine kinase inhibitor therapy: a multicenter phase II trial.

Speaker: Dong Pei

Affiliation: Sun Yat-sen University Cancer Center

06

Description No.: 4540

标题：Preliminary results from a phase II clinical study of first-line drugs combined with stereotactic body radiotherapy (SBRT) in the treatment of oligoprogressive renal cell carcinoma.

Preliminary results from a phase II clinical study of first-line drug therapy combined with stereotactic radiosurgery (SBRT) in oligoprogressive renal cell carcinoma.

报告人：Xinyue Zhang

Affiliation: Sun Yat-sen University Cancer Center

07

Abstract No.: 4544

标题：Anlotinib combined with sintilimab as first-line treatment in patients with advanced non-clear cell renal cell carcinoma (nccRR): Preliminary results from an exploratory prospective multicentre clinical study.

Anlotinib in combination with sintilimab as first-line treatment in patients with non-clear cell renal cell carcinoma (nccRCC): preliminary results from an exploratory prospective multicenter clinical study.

Speaker: Dong Pei

Affiliation: Sun Yat-sen University Cancer Center

08

Description No.: 4568

标题：Preliminary efficacy and safety results from RC48-C017: A phase II study of neoadjuvant treatment with disitamab vedotin plus toripalimab in patients with muscle invasive bladder cancer (MIBC) with HER2 expression.

Preliminary efficacy and safety results from the RC48-C017 study: A Phase II study of vedicitumab in combination with toripalimab neoadjuvant in patients with positive HER2 expression in muscle-invasive bladder cancer (MIBC).

Speaker: Sheng Xinan

Affiliation: Peking University Cancer Hospital

09

Description Number: 4573

标题：Updated results from a phase II study of penpulimab plus anlotinib as first-line therapy in metastatic urothelial cancer (mUC).

Updated results from a Phase II study of penpulimab in combination with anlotinib in the first-line treatment of metastatic urothelial carcinoma (mUC).

Speaker: Yang Bo

Unit: General Hospital of the Chinese People's Liberation Army

10

Abstract: 4594

标题：Phase II trial of intravesical camrelizumab in BCG-unresponsive high-risk non-muscle invasive bladder cancer.

A phase II trial of intravesical camrelizumab in patients with BCG-unresponsive, high-risk non-muscle-invasive bladder cancer.

Speaker: Shen Yijun

Affiliation: Fudan University Cancer Hospital

11

Abstract: 4596

标题：A phase II clinical trial of toripalimab combined with cisplatin plus gemcitabine chemotherapy as neoadjuvant treatment for muscle-invasive bladder cancer.

A phase II clinical trial of toripalimab in combination with cisplatin plus gemcitabine chemotherapy as neoadjuvant therapy for muscle-invasive bladder cancer.

Speaker: Rong Yang

Affiliation: Drum Tower Hospital, Nanjing University School of Medicine

12

Abstract:4603

标题：Differentiating between adrenocortical carcinoma and pheochromocytoma by radiomics features at CT: A multi-institutional retrospective study.

Differentiation of adrenocortical carcinoma and pheochromocytoma based on CT radiomics: a multiagency retrospective study.

报告人：Jingtong Zhang

Affiliation: Sun Yat-sen University Cancer Center

13

Abstract Number: TPS4625

标题：Adjuvant or rescue disitamab vedotin (RC48-ADC) for high-risk non-muscle invasive bladder cancer with HER2 overexpression: A phase II multi-center study.

Adjuvant or salvage vedicitumab (RC48-ADC) in high-risk non-muscle-invasive bladder cancer with HER2 overexpression: a multicenter phase II study.

Speaker: Junru Chen

Affiliation: West China Hospital, Sichuan University

Prostate, testicle, and penile cancers

14

Abstract:5044

标题：Albumin-bound paclitaxel, cisplatin, and bleomycin combination with tislelizumab for stage IV squamous cell carcinoma of the penis without surgical indications: A single-arm, single-center prospective phase II clinical study.

Albumin-conjugated paclitaxel, cisplatin, and bleomycin in combination with tislelizumab in stage IV penile squamous cell carcinoma without indication for surgery: a single-arm, single-center, prospective, phase II clinical study.

报告人:Xingli Shan

Affiliation: Cancer Hospital, Chinese Academy of Medical Sciences

15

Abstract No.: 5047

标题：A phase 1, multi-center, open-label, dose-escalation, and dose-expansion study of CBP-1018, a bi-ligand-drug conjugate in patients with heavily treated advanced solid tumors.

CBP-1018 is a two-ligand-drug conjugate in patients with advanced solid tumors who have received prior treatment: a Phase I multicenter, open-label, dose-escalation and expansion study.

Speaker: Kaiwen Lee

Affiliation: Sun Yat-sen Memorial Hospital, Sun Yat-sen University

16

Abstract: 5048

标题：Patient-reported outcomes (PROs) for rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy (ADT) in high-volume, metastatic, hormone-sensitive prostate cancer (mHSPC): An analysis of the CHART randomized, open-label, phase 3 trial.

CHART Study: Patient-Reported Outcomes (PROs): Revilutamide Versus Bicalutamide in Combination With Androgen Deprivation Therapy (ADT) in High-Load, Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): A Randomized, Open-label, Phase III Trial Analysis.

Speaker: Dingwei Yip

Affiliation: Fudan University Cancer Hospital

17

Abstract: 5059

标题：Rezvilutamide (REZ) plus docetaxel (DOC) in patients (pts) with chemo-naïve metastatic castration-resistant prostate cancer (mCRPC) after progression on abiraterone (ABI).

Efficacy of revilutamide (REZ) in combination with docetaxel (DOC) in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) who have progressed after abiraterone (ABI) therapy.

Speaker: Zhenhua Liu

Affiliation: West China Hospital, Sichuan University

18

Abstract:5071

标题：The effect of ACEi/ARB on survival outcome of patients with mCRPC treated with abiraterone.

Effect of ACE inhibitors/angiotensin receptor blockers on survival outcomes in patients with mCRPC treated with abiraterone

Reported by: Junliang Zhao

Affiliation: Sun Yat-sen University Cancer Center

19

Abstract: 5082

标题：PROact: A prospective phase II study to evaluate olaparib plus abiraterone and prednisone combination therapy in patients with metastatic hormone sensitive prostate cancer with HRR gene mutation.

PROact: A prospective phase II study to evaluate the efficacy of olaparib in combination with abiraterone and prednisone in patients with metastatic hormone-sensitive prostate cancer harboring HRR gene mutations.

Speaker: Junlong Zhuang

Affiliation: Drum Tower Hospital, Nanjing University School of Medicine

20

Abstract Number: TPS5107

标题：SAVE: A prospective, single-arm, single-center clinical study of disitamab vedotin in combination with toripalimab in patients with advanced penile cancer that has progressed or is intolerant to cisplatin chemotherapy.

SAVE: A prospective, single-arm, single-center clinical study evaluating vedicitumab in combination with toripalimab in patients with advanced penile cancer who have progressed or are intolerant to cisplatin chemotherapy.

Speaker: Fang Yuan

Affiliation: Affiliated Cancer Hospital of Chongqing University

International blockbuster

01

Abstract Number: LBA4517

标题：Perioperative sacituzumab govitecan (SG) alone or in combination with pembrolizumab (Pembro) for patients with muscle-invasive urothelial bladder cancer (MIBC): SURE-01/02 interim results.

围手术期 sacituzumab govitecan (SG) 单独或与帕博利珠单抗(Pembro)联合用于肌层浸润性尿路上皮膀胱癌(MIBC)患者:SURE-01/02 中期结果。

报告人:Antonio Cigliola

Unit: IRCCS San Rafael Hospital

02

Abstract Number: LBA5000

标题：Cabazitaxel with abiraterone versus abiraterone alone randomized trial for extensive disease following docetaxel: The CHAARTED2 trial of the ECOG-ACRIN Cancer Research Group (EA8153).

A Randomized Trial of Cabazitaxel in Combination With Abiraterone Versus Abiraterone Monotherapy for Extensive-Phase Disease After Docetaxel Treatment: The ECOG-ACRIN Cancer Study Group CHAARTED2 Trial (EA8153).

报告人:Christos Kyriakopoulos

Unit: University of Wisconsin Carbon Cancer Center

03

Abstract Number: LBA5002

标题：A randomized, double-blind, placebo-controlled trial of metformin in reducing progression among men on expectant management for low-risk prostate cancer: The MAST (Metformin Active Surveillance Trial) study.

A Randomized, Double-Blind, Placebo-Controlled Trial of Metformin to Reduce Disease Progression in Low-Risk Prostate Cancer in Men Awaiting Treatment: The MAST (Metformin Active Surveillance Trial) Study.

Presented by Anthony Joshua

Unit: St. Vincent's Hospital

04

Abstract Number: LBA5004

标题：MANCAN2: A multicentre randomised controlled trial of self-help cognitive behavioural therapy (CBT) to manage hot flush and night sweats (HFNS) symptoms in patients with prostate cancer receiving androgen deprivation therapy (ADT).

MANCAN2 study: a multicentre randomized controlled trial investigating the effects of self-help cognitive behavioural therapy (CBT) for the treatment of hot flashes and night sweats (HFNS) symptoms in prostate cancer patients undergoing androgen deprivation therapy (ADT).

报告人：Simon Crabb

Affiliation: University of Southampton

05

Abstract Number: LBA5014

标题：Blood-based markers of differential efficacy of bipolar androgen therapy and enzalutamide in the randomized TRANSFORMER trial.

Blood markers of differential efficacy of bipolar androgen therapy and enzalutamide in a randomized TRANSFORMER trial.

报告人：Samuel Denmeade

Affiliation: Johns Hopkins University

Note: Rankings are in no particular order, according to the abstract number

If there is any omission or any questions, please leave us a message~

编辑:Gardenia审校:Gardenia执行:Gardenia

This platform aims to deliver more medical information to healthcare professionals. The content published on this platform should not be used as a substitute for professional medical guidance in any way, nor should it be regarded as diagnosis and treatment advice. If such information is used for purposes other than understanding medical information, the platform does not assume relevant responsibilities. This platform does not mean that it agrees with its descriptions and views on the published content. If copyright issues are involved, please contact us, and we will deal with it as soon as possible.

Yimaitong is a professional online doctor platform, and the mission of the platform is to "sense the pulse of the world's medicine and help China's clinical decision-making". Yimaitong has a series of products such as "Clinical Guidelines", "Medication Reference", "Medical Literature King", "Yizhiyuan", "eYantong" and "ePulse", which fully meet the needs of medical workers in clinical decision-making, obtaining new knowledge and improving scientific research efficiency.